Every DEF 14A that Revelation Biosciences, Inc. Warrant (REVBW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow REVBW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVBW filings page.
Revelation Biosciences is asking stockholders to approve routine 2026 annual meeting matters and a broad reverse stock split authorization. Investors will vote on electing Jennifer Carver as Class A director through the 2029 meeting, authorizing the board to implement one or more reverse stock splits within a range of 1-for-2 to up to 1-for-250 within one year, and ratifying Baker Tilly US, LLP as auditor for 2026.
The company cites Nasdaq’s $1.00 minimum bid rule as the main reason for the split flexibility and notes several prior reverse splits used to regain compliance. There were 3,908,420 common shares outstanding as of the April 30, 2026 record date. The proxy also details governance structure, director pay, and 2025 executive compensation, including salary increases and cash bonuses for the CEO and CFO despite a 2025 net loss.
Revelation Biosciences, Inc. is calling a virtual special stockholder meeting on March 18, 2026 to vote on a key financing-related proposal. The main item is approval for the reservation and issuance of common shares underlying newly issued Class J Common Stock Warrants, where exercises could exceed 20% of shares outstanding and trigger Nasdaq’s Rule 5635(d) share issuance cap.
These Class J warrants were issued on January 23, 2026 in a warrant inducement deal tied to the exercise of 2,136,251 Class I warrants at an exercise price of $8.80 per share and are exercisable for five years at an exercise price of $3.44 per share. As of January 26, 2026, there were 10,492,469 shares of common stock outstanding, each with one vote. A second proposal would allow adjournment of the meeting if there are not enough proxies to approve the warrant share issuance. The board unanimously recommends voting in favor of both proposals.